Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 09 - 20 symbols : MRTX save search
Mirati Therapeutics Announces Long-term Survival Results from an Exploratory Analysis of Sitravatinib plus Nivolumab in Patients with Non-squamous Non-Small Cell Lung Cancer Who are Resistant to Checkpoint Inhibitors
Published: 2021-09-20 (Crawled : 14:15) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.78%
H: 11.36%
C: 3.1%
lung cancer results cancer nivolumab
Mirati Therapeutics Appoints David Meek as Chief Executive Officer
Published: 2021-09-20 (Crawled : 12:15) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.54%
H: 0.0%
C: 0.0%
QURE | $4.68 -0.64% -0.64% 550K
|
Health Technology
|
| O: -2.68%
H: 4.17%
C: 2.46%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.78%
H: 11.36%
C: 3.1%
ETTX | $2.19 -0.46% 0.46%
|
Health Technology
|
| O: -0.64%
H: 25.56%
C: 11.65%
therapeutics
Mirati Therapeutics Announces Positive Phase 2 Topline Results for Investigational Adagrasib in Patients with KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
Published: 2021-09-20 (Crawled : 12:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.78%
H: 11.36%
C: 3.1%
phase 2 lung cancer positive results cancer topline
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.